Skip to content

Who We Are

OUR PASSION

Why do we exist?

“Our passion is translating science and technology to save lives – that’s as simple as it is.”

Dr Zhou Lihan 
Co-Founder and Chief Executive Officer

OUR MISSION

How will we save lives?

DISCOVER

new biology and biomarkers 

DEVELOP

game-changing applications 

DIAGNOSE

diseases early

OUR STORY

Too Heng Phon

We are a homegrown Singapore-headquartered Biotech startup with an expanding global presence in USA, China, and Japan

“The ‘S’ in our name MiRXES stands for Singapore. We believe in the importance of setting up core capabilities locally so that, apart from saving lives, we can contribute to the Biotech and startup ecosystem.”

Associate Professor Too Heng-Phon 
Co-Founder and Non-Executive Chairman

The MiRXES journey began when a team of researchers in the lab took a leap of faith and formed the startup in 2014

“In the first week of spinning off, we secured major contracts with multinational pharma companies and research institutions. That was our point of no return and, though we are today a leader in RNA research and applications, we remain at heart a startup. The MiRXES story is the story of every single person in the team.”

Dr Zhou Lihan
Co-Founder and Chief Executive Officer

Zhou Lihan
Zou Ruiyang

Our products and services leverage on a patented, best-in-class, quantitative reverse transcriptase polymerase chain reaction (RT-qPCR) technology platform that can quantify microRNAs, the smallest pieces of genetic material.

“As scientists, we developed this versatile technology platform and became accidental entrepreneurs when MiRXES was spun off from the lab to develop clinical and research applications that could be commercialised and made accessible to those who need them.”

Dr Zou Ruiyang
Co-Founder and Chief Technology Officer

OUR COMMITMENT

We seek to harness our world-leading microRNA research and technology platform to discover and incubate game-changing biotech applications across the medical, pharmaceutical, agri-tech, and vet-tech industries.

Tukang
Group 1

Through our pioneering microRNA biomarker profiling efforts, we work with our partners to develop game-changing applications and accelerate them to market.

We are committed to building a global ecosystem with a strong network of clinicians, researchers, and corporate partners to transform innovative science into affordable, accurate, and accessible solutions that can eradicate diseases and improve lives.

Group 3

OUR MILESTONES

2005 - Academic Beginnings
Professor Too Heng-Phon's research group at the National University of Singapore (NUS) published its first microRNA paper.
2010 - Technology Proof-of-Concept
R&D team incubated by Singapore's Agency for Science, Technology and Research (A*STAR) to develop its patented microRNA detection technology into a versatile technology platform.
2012 - Clinical Proof-of-Concept
R&D team started its first clinical study, in collaboration with the Singapore Gastric Cancer Consortium (SGCC), to show that circulating microRNAs can be novel biomarkers for early detection of cancer.
2014 - Commercialization
MiRXES Pte Ltd founded as spin-off from A*STAR to commercialize its industry-leading qPCR technology platform.
2015 - Research and Clinical Application
Life science research reagents and services launched globally.

Started large-scale prospective clinical validation of GASTROClear, the world's first microRNA-based blood test for stomach cancer, in collaboration with SGCC.
2016 - Manufacturing Capabilities Set-Up
Singapore manufacturing site established at JTC MedTech Hub.

China operations started in Hangzhou.

Received seed funding from Venturecraft.

Named Most Promising Startup at Emerging Enterprise Awards.
2017 - Clinical Pipeline Expansion
Established partnerships for biomarker discovery in oncology, cardiovascular, metabolic, neuroscience, and infectious diseases.

Singapore manufacturing site certified under ISO13485 quality management system.

CE-mark for GASTROClear.

Co-founders received A*STAR Scientist-Entrepreneur Award.
2018 - Global Partnerships Expansion
Strategic collaboration with Johnson & Johnson and Janssen Pharmaceutica announced at J.P. Morgan Healthcare Conference.

Non-coding RNA (ncRNA) core facilities jointly established with NUS Medical School and Beth Israel Deaconess Medical Center.

Founded Ark Bio as investment holding company.
2019 - Regulatory Approval
GASTROClear received Singapore Health Science Authority (HSA) approval for IVD use as adjunctive test for detection of stomach cancer and launched in Singapore through Tan Tock Seng Hospital's (TTSH) Molecular Diagnostic Laboratory.
2020 - Accelerating Clinical Adoption
Organised first ncRNA Symposium and Summit to accelerate clinical adoption of microRNA-based diagnostics.

Became product owner of Fortitude Kit, a SARS-CoV-2 RT-PCR test developed by A*STAR and TTSH. Deployed for COVID-19 testing in 13 Singapore hospitals and labs, and more than 20 countries globally.

Established Japan subsidiary.

Milestones

2005
Professor Too Heng-Phon's research group publishes its first microRNA paper.
2012
The lab conducts its first clinical study, proving the hypothesis that circulating miRNAs could serve as novel biomarkers for early detection of gastric cancer.
2015
MiRXES Life Science research use products launched worldwide.
2017
Singapore manufacturing certified under ISO 13485 quality management system.
First IVD product, GASTROClear, received CE-mark.
Co-founders received A*STAR Scientist-Entrepreneur Award.
2019
GASTROClear received Singapore Health Science Authority (HSA) approval.
GASTROClear commercial launch in Singapore and China.
2010
The team is incubated by A*STAR to develop their miRNA detection technology into a versatile technology platform.
2014
MiRXES Pte Ltd founded as spin-off from A*STAR.
2016
Singapore manufacturing site established at JTC MedTech Hub.
China operations started in Hangzhou.
Received seed funding from Venturecraft.
Named Most Promising Startup at Emerging Enterprise Awards.
2018
Strategic collaboration with Johnson & Johnson announced at J.P. Morgan Healthcare Conference.
Founded Ark Bio as investment holding company for product commercialization.